Phase 1b Study of the PKMYT1 Inhibitor RP-6306 in Combination With FOLFIRI for the Treatment of Advanced Solid Tumors (MINOTAUR Study)
Study of RP-6306 in Combination with FOLFIRI in Patients with Advanced Solid Tumors (Colon, Esophageal, or GI Cancer)
Sponsor: Repare Therapeutics
Enrolling: Male and Female Patients
IRB Number: AAAT9701
U.S. Govt. ID: NCT05147350
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test how safe RP-6306 and FOLFIRI are when given together at different doses and on different schedules, and test how well RP-6306 and FOLFIRI work together to shrink solid tumors in the body. This is the first time RP-6306 is being given with FOLFIRI to humans. Cancers include esophageal cancer and colon and rectal cancer.
This study is closed
Investigator
Ryan Moy, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with colon, esophageal, or GI cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE